The World Anti-Doping Agency (WADA) Prohibited List is updated annually and prohibits a broad range of peptides and peptide hormones in sport. For competitive athletes subject to WADA-code testing, understanding which peptides are prohibited, how testing works, and what the consequences of a positive test are is essential. The landscape is complex: some research peptides are explicitly listed, others fall under catch-all prohibitions, and detection methods continue to advance.
Research context only. The peptides discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
As of 2025, BPC-157 is not explicitly named on the WADA Prohibited List and there is no confirmed validated detection test for it in standard anti-doping panels. However, it could theoretically fall under catch-all language prohibiting substances with similar biological effects to growth factors. Athletes should verify with their specific sport's governing body or national anti-doping agency before use.
What WADA Prohibits: Peptide Categories
WADA's Prohibited List (Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics) covers peptides across several categories. Explicitly prohibited compounds relevant to the research peptide space include: all growth hormone releasing hormones (CRH, GHRH, GnRH and analogues), GH secretagogues including GHRPs (GHRP-2, GHRP-6), ghrelin analogues (MK-677/Ibutamoren is specifically listed), somatomedins including IGF-1 and its analogues (IGF-1 LR3, IGF-1 DES, MGF).
Additionally, WADA prohibits erythropoietin and related compounds, melanocortin receptor agonists (which covers PT-141 and Melanotan II), and — critically — any "substance with a similar chemical structure or similar biological effect(s)" to prohibited compounds. This catch-all language means peptides not explicitly named can still constitute violations if they mimic the effects of listed compounds. BPC-157 and TB-500 are not currently explicitly listed but could be argued to fall under growth factor and tissue repair categories depending on interpretation.
Detection Methods and Windows
Peptide detection in sport has historically been challenging because peptides are naturally occurring substances present in biological samples at low concentrations, and exogenous administration is difficult to distinguish from endogenous production. Modern testing uses immunoassay screening followed by LCMS/MS (liquid chromatography-tandem mass spectrometry) confirmation, which can detect peptides at picogram-per-millilitre concentrations.
Detection windows vary by peptide and route of administration. Growth hormone-related peptides and GHRPs are typically detectable in urine for 24–72 hours post-administration, with blood testing extending this to 24 hours for endogenous GH markers (GH pulse pattern detection). MK-677 (oral) has a detection window of approximately 24–48 hours in urine. IGF-1 analogues may have slightly longer windows. The detection science is advancing rapidly — compounds previously undetectable are increasingly identifiable as methods improve.
BPC-157 and TB-500: Current Status
BPC-157 and TB-500 (thymosin beta-4) occupy a regulatory grey zone. Neither is currently explicitly named on the WADA Prohibited List as of 2025. However, TB-500/thymosin beta-4 is classified as a prohibited peptide under S2.2 (growth factors and growth factor modulators) by many sports authorities, and WADA has signalled intent to monitor it. BPC-157 is not currently prohibited and has no confirmed reliable detection method in standard sports testing.
The critical caution: absence from the explicit list does not guarantee permissibility under the catch-all "similar biological effect" clause. An athlete using any non-listed substance should check with their sport's governing body directly, and many national anti-doping organisations offer confidential inquiries for athletes seeking clarification without self-reporting.
Strict Liability: What It Means for Athletes
WADA operates under strict liability — an athlete is responsible for any prohibited substance found in their sample, regardless of intent, knowledge, or how it got there. This means research peptide use carries real competition risk for athletes. "I didn't know it was prohibited" or "my supplement contained it without labelling" are not defences that eliminate sanctions, though they may reduce them in specific cases (Significant Fault assessments).
The practical implication: competitive athletes under WADA-code testing should treat all research peptides as potentially prohibited and consult anti-doping authorities before use. The recreational athlete not subject to testing has a different risk calculus — but should be aware of the legal and regulatory status in their jurisdiction independently of WADA rules.
Peptides and WADA Status Reference
| Peptide | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| CJC-1295, Sermorelin | Prohibited | S2 — GHRH analogues | Yes — immunoassay + LCMS/MS | Banned |
| GHRP-2, GHRP-6, Ipamorelin | Prohibited | S2 — GH secretagogues | Yes — LCMS/MS, ~24–72h window | Banned |
| MK-677 (Ibutamoren) | Prohibited | S2 — explicitly named | Yes — oral ~24–48h | Banned |
| IGF-1 LR3, IGF-1 DES | Prohibited | S2 — IGF analogues | Yes — LCMS/MS | Banned |
| PT-141, Melanotan II | Prohibited | S2 — melanocortin agonists | Emerging methods | Banned |
| BPC-157 | Not explicitly listed (2025) | Potential S2 catch-all | No confirmed detection test | Verify before use |
| TB-500 / Thymosin β-4 | Prohibited by many federations | S2 — growth factors | Yes — LCMS/MS | Banned in most sports |
Also Available at Apollo Peptide Sciences
Apollo Peptide Sciences carries independently tested research-grade compounds. Products ship from the USA with published purity certificates.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
As of 2025, BPC-157 is not explicitly named on the WADA Prohibited List and there is no confirmed validated detection test for it in standard anti-doping panels. However, it could theoretically fall under catch-all language prohibiting substances with similar biological effects to growth factors. Athletes should verify with their specific sport's governing body or national anti-doping agency before use.
Yes — strict liability means a positive test is a positive test regardless of source. Some GHRP and peptide contamination has been identified in unlabelled or mislabelled supplements. Athletes using any supplement should use WADA-certified products (NSF Certified for Sport, Informed Sport) and check independently. Research peptides are generally not relevant here as they are not typically used as supplement ingredients.
As of 2025, GLP-1 agonists like semaglutide and tirzepatide are not on the WADA Prohibited List. They are approved medications without established performance-enhancing effects in sport (weight loss may affect sport-specific performance differently). WADA does monitor these as they are used by increasing numbers of athletes.
This varies by compound. GHRPs typically clear in 24–72 hours (urine). MK-677 clears in approximately 24–48 hours (oral). IGF-1 analogues may take slightly longer. However, blood-based biomarker tests (GH ratio, GH pulse pattern analysis) can detect GH axis manipulation for longer periods. Athletes should not rely on simple calculations — detection technology is continuously improving.